Blistering report against Tamiflu cites possible harm to users - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

Blistering report against Tamiflu cites possible harm to users

Posted: Updated:
  • SPONSORED BY SOUTHEAST HEALTHMore>>

  • Quinn signs epinephrine law for Illinois schools

    Quinn signs epinephrine law for Illinois schools

    Wednesday, July 30 2014 6:36 PM EDT2014-07-30 22:36:36 GMT
    A new bill signed into Illinois law says trained personnel at schools statewide will be able to administer injectable epinephrine for those appearing to have strong allergic reactions.
    A new bill signed into Illinois law says trained personnel at schools statewide will be able to administer injectable epinephrine for those appearing to have strong allergic reactions.
  • Illinois Medicaid restricts use of hepatitis drug

    Illinois Medicaid restricts use of hepatitis drug

    Wednesday, July 30 2014 2:41 PM EDT2014-07-30 18:41:49 GMT
    Illinois is placing tight restrictions on a new hepatitis C drug that costs $1,000 per pill. Medicaid patients must meet 25 criteria and get prior approval before the government health care program will pay for...
    Illinois is placing tight restrictions on a new hepatitis C drug that costs $1,000 per pill. Medicaid patients must meet 25 criteria and get prior approval before the government health care program will pay for Sovaldi.
  • Surgeon general issues skin cancer warning

    Surgeon general issues skin cancer warning

    Wednesday, July 30 2014 11:04 AM EDT2014-07-30 15:04:38 GMT
    Nearly 5 million people are treated for skin cancer each year - more than cases of breast, prostate, lung and colon cancer combined.
    Nearly 5 million people are treated for skin cancer each year - more than cases of breast, prostate, lung and colon cancer combined.
(KFVS) - Researchers with the University of Oxford found that Tamiflu not only does not do any good in fighting the flu. It might actually harm those who take it.

It was a blistering report that says millions of dollars have been wasted on the anti-viral drug. Researchers say Tamiflu only slightly reduces flu symptoms and failed to reduce hospital admissions. Not only that, the report indicates Tamiflu may actually harm those who take it.

"And that third more worryingly, that they have a number of adverse effects, that includes nausea, vomiting and headaches, but also importantly some really serious adverse events, which include psychiatric adverse events, renal adverse events and metabolic adverse events which include raising your blood sugar," said Professor Carl Heneghan, from the University of Oxford, who is one of the authors of the Cochrane report .

The makers of Tamiflu strongly disagree with the findings of this report.

Representatives respond by saying Tamiflu is backed up by dozens of clinical studies that shows it does exactly what it claims to do.

"Tamiflu was first licensed in 1999 and we're now in 2014, so it's been on the market for some 15 years," said Barry Clinch, the principal scientist working on Tamiflu for the pharmaceutical company Roche. "It's been approved by 100 regulators in individual countries around the world and 130 million patients have been treated with this medicine. So when I look at that in that context, versus one report, and then you also ask the question of "What about pandemic preparedness?" WHO recommended the use of the drug, CDC in the US, the European equivalent also recommended the use of the drug, so there's a clear consensus across all of those people."

Researchers who say it doesn't work recommend better use of flu vaccines to keep people from ever getting the virus in the first place.

Copyright 2014 KFVS. All rights reserved. CBS contributed to this report.
Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.